Daniel Fowler, Marta Barisa, Alba Southern, Callum Nattress, Elizabeth Hawkins, Eleni Vassalou, Angeliki Kanouta, John Counsell, Enrique Rota, Petra Vlckova, Benjamin Draper, Tessa De Mooij, Andrea Farkas, Helena Brezovjakova, Alfie T Baker, Katia Scotlandi, Maria C Manara, Chris Tape, Kerry Chester, John Anderson, Jonathan Fisher
T cell-based cancer immunotherapy has typically relied on membrane-bound cytotoxicity enhancers such as chimeric antigen receptors expressed in autologous αβ T cells. These approaches are limited by tonic signaling of synthetic constructs and costs associated with manufacturing. γδ T cells are an emerging alternative for cellular therapy, having innate antitumor activity, potent antibody-dependent cellular cytotoxicity, and minimal alloreactivity. We present an immunotherapeutic platform technology built around the innate properties of the Vγ9Vδ2 T cell, harnessing specific characteristics of this cell type and offering an allocompatible cellular therapy that recruits bystander immunity...
May 29, 2024: Science Translational Medicine